Biomerica, Inc. reported a modest decrease in net sales to $5.3 million due to global tariff uncertainties impacting international orders and a shift in product mix. Gross profit was $498,000, down from $611,000. Operating expenses were reduced by $1.3 million, resulting in a 19% improvement in operating loss to $5.1 million.

Cash used in operating activities improved significantly to $3.8 million, a $1.5 million improvement from the prior year. Biomerica strategically focuses on inFoods® IBS opportunities, at-home tests in the MENA region, and H. pylori antigen sales in the U.S. and Europe for revenue growth.

Key milestones achieved in fiscal year 2025 include the submission of a PLA code application for inFoods® IBS, peer-reviewed validation of clinical study results, IVDR certification, MENA expansion, direct-to-consumer launch, and intellectual property growth. Biomerica remains dedicated to driving growth through innovation and strategic partnerships.

Read more at GlobeNewswire: Biomerica Reports Fiscal 2025 Year End Results